Posted on

Key players in psoriasis offer strong support through branded digital channels to Australian patients, says GlobalData

Share

The psoriasis (PsO) therapeutics market in Australia is dominated by biologics such as anti-TNF, anti-IL-17, anti-IL-23, and anti-IL-12/anti-IL-23 therapies. Among these, stiff competition exists among AbbVie’s Skyrizi, Novartis’ Cosentyx, Eli Lilly’s Taltz and Sun Pharma’s Ilumya. Against this backdrop, the pharma giants offer strong support to PsO patients in the branded space through digital channels, says GlobalData, a leading data and analytics company.
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of PsO in Australia is estimated to increase at an annual growth rate of 1.37% from 521,584 in 2021 to 561,567 in 2027.
In Australia, …

Read More